Immunoprofiles of colorectal cancer from Lynch syndrome

Joanna Walkowska; Thomas Kallemose; Göran Jönsson; Mats Jönsson; Ove Andersen; Mads Hald Andersen; Inge Marie Svane; Anne Langkilde; Mef Nilbert; Christina Therkildsen

doi:10.1080/2162402x.2018.1515612

Immunoprofiles of colorectal cancer from Lynch syndrome

Joanna Walkowska, Thomas Kallemose, Göran Jönsson, Mats Jönsson, Ove Andersen, Mads Hald Andersen, Inge Marie Svane, Anne Langkilde, Mef Nilbert, Christina Therkildsen

Department of Clinical Medicine

2 Citations (Scopus)

Abstract

Colorectal cancers associated with Lynch syndrome are characterized by defective mismatch repair, microsatellite instability, high mutation rates, and a highly immunogenic environment. These features define a subset of cancer with a favorable prognosis and high likelihood to respond to treatment with anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) drugs. With the aim to define immune-evasive mechanisms and a potential impact hereof in colorectal cancers from Lynch syndrome versus hereditary cases with retained mismatch repair function, we immunohistochemically and transcriptionally profiled 270 tumors. Lynch syndrome-associated tumors showed an overrepresentation of tumor-infiltrating CD3, CD8 and CD68 positive cells, loss of beta-2-microglobulin (B2M) and up-regulation of PD-L1 on tumor cells. The gene expression signature of Lynch syndrome tumors was characterized by upregulation of genes related to antigen processing and presentation, apoptosis, natural killer cell-mediated cytotoxicity, and T cell activation. Tumors with loss of B2M and up-regulation of PD-L1 showed distinctive immunogenic profiles. In summary, our data demonstrate a complex tumor-host interplay where B2M loss and PD-L1 up-regulation influence immunological pathways and clinical outcome in Lynch syndrome tumors. Immunological classification may thus aid in the preselection of colorectal cancers relevant for treatment with anti-PD-1/PD-L1 therapies.

Original language	English
Article number	e1515612
Journal	OncoImmunology
Volume	8
Issue number	1
Number of pages	9
ISSN	2162-4011
DOIs	https://doi.org/10.1080/2162402x.2018.1515612
Publication status	Published - 2 Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/2162402x.2018.1515612

2162402X.2018.1515612?needAccess=trueFinal published version, 2.7 MB

Cite this

@article{a7b589df5e2e439fb8fae835acd8c18a,

title = "Immunoprofiles of colorectal cancer from Lynch syndrome",

abstract = "Colorectal cancers associated with Lynch syndrome are characterized by defective mismatch repair, microsatellite instability, high mutation rates, and a highly immunogenic environment. These features define a subset of cancer with a favorable prognosis and high likelihood to respond to treatment with anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) drugs. With the aim to define immune-evasive mechanisms and a potential impact hereof in colorectal cancers from Lynch syndrome versus hereditary cases with retained mismatch repair function, we immunohistochemically and transcriptionally profiled 270 tumors. Lynch syndrome-associated tumors showed an overrepresentation of tumor-infiltrating CD3, CD8 and CD68 positive cells, loss of beta-2-microglobulin (B2M) and up-regulation of PD-L1 on tumor cells. The gene expression signature of Lynch syndrome tumors was characterized by upregulation of genes related to antigen processing and presentation, apoptosis, natural killer cell-mediated cytotoxicity, and T cell activation. Tumors with loss of B2M and up-regulation of PD-L1 showed distinctive immunogenic profiles. In summary, our data demonstrate a complex tumor-host interplay where B2M loss and PD-L1 up-regulation influence immunological pathways and clinical outcome in Lynch syndrome tumors. Immunological classification may thus aid in the preselection of colorectal cancers relevant for treatment with anti-PD-1/PD-L1 therapies.",

author = "Joanna Walkowska and Thomas Kallemose and G{\"o}ran J{\"o}nsson and Mats J{\"o}nsson and Ove Andersen and Andersen, {Mads Hald} and Svane, {Inge Marie} and Anne Langkilde and Mef Nilbert and Christina Therkildsen",

year = "2019",

month = jan,

day = "2",

doi = "10.1080/2162402x.2018.1515612",

language = "English",

volume = "8",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - Immunoprofiles of colorectal cancer from Lynch syndrome

AU - Walkowska, Joanna

AU - Kallemose, Thomas

AU - Jönsson, Göran

AU - Jönsson, Mats

AU - Andersen, Ove

AU - Andersen, Mads Hald

AU - Svane, Inge Marie

AU - Langkilde, Anne

AU - Nilbert, Mef

AU - Therkildsen, Christina

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Colorectal cancers associated with Lynch syndrome are characterized by defective mismatch repair, microsatellite instability, high mutation rates, and a highly immunogenic environment. These features define a subset of cancer with a favorable prognosis and high likelihood to respond to treatment with anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) drugs. With the aim to define immune-evasive mechanisms and a potential impact hereof in colorectal cancers from Lynch syndrome versus hereditary cases with retained mismatch repair function, we immunohistochemically and transcriptionally profiled 270 tumors. Lynch syndrome-associated tumors showed an overrepresentation of tumor-infiltrating CD3, CD8 and CD68 positive cells, loss of beta-2-microglobulin (B2M) and up-regulation of PD-L1 on tumor cells. The gene expression signature of Lynch syndrome tumors was characterized by upregulation of genes related to antigen processing and presentation, apoptosis, natural killer cell-mediated cytotoxicity, and T cell activation. Tumors with loss of B2M and up-regulation of PD-L1 showed distinctive immunogenic profiles. In summary, our data demonstrate a complex tumor-host interplay where B2M loss and PD-L1 up-regulation influence immunological pathways and clinical outcome in Lynch syndrome tumors. Immunological classification may thus aid in the preselection of colorectal cancers relevant for treatment with anti-PD-1/PD-L1 therapies.

AB - Colorectal cancers associated with Lynch syndrome are characterized by defective mismatch repair, microsatellite instability, high mutation rates, and a highly immunogenic environment. These features define a subset of cancer with a favorable prognosis and high likelihood to respond to treatment with anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) drugs. With the aim to define immune-evasive mechanisms and a potential impact hereof in colorectal cancers from Lynch syndrome versus hereditary cases with retained mismatch repair function, we immunohistochemically and transcriptionally profiled 270 tumors. Lynch syndrome-associated tumors showed an overrepresentation of tumor-infiltrating CD3, CD8 and CD68 positive cells, loss of beta-2-microglobulin (B2M) and up-regulation of PD-L1 on tumor cells. The gene expression signature of Lynch syndrome tumors was characterized by upregulation of genes related to antigen processing and presentation, apoptosis, natural killer cell-mediated cytotoxicity, and T cell activation. Tumors with loss of B2M and up-regulation of PD-L1 showed distinctive immunogenic profiles. In summary, our data demonstrate a complex tumor-host interplay where B2M loss and PD-L1 up-regulation influence immunological pathways and clinical outcome in Lynch syndrome tumors. Immunological classification may thus aid in the preselection of colorectal cancers relevant for treatment with anti-PD-1/PD-L1 therapies.

U2 - 10.1080/2162402x.2018.1515612

DO - 10.1080/2162402x.2018.1515612

M3 - Journal article

C2 - 30546958

SN - 2162-4011

VL - 8

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - e1515612

ER -

Immunoprofiles of colorectal cancer from Lynch syndrome

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this